Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

70.39 -0.66 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corp

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Reverses Losses Amid Nvidia Fanfare
Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine. 
Via Talk Markets
Gold Moves Higher; Medtronic Posts Upbeat Results
Via Benzinga
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?
Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the ongoing Russia-Ukraine conflict. 
Via Benzinga
Topics Energy
Exposures Fossil Fuels
Cracking The Code: Understanding Analyst Reviews For Incyte
Via Benzinga
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
Sales of the company's two key products, Jakafi and Opzelura, jumped. 
Via Investor's Business Daily
What's Going On With Incyte Shares Tuesday?
Incyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development. 
Via Benzinga
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations. 
Via Benzinga
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
The company is discontinuing development of one drug and pausing enrollment in the study of another. 
Via Investor's Business Daily
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Via Benzinga
Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY).
NASDAQ:INCY may be ready to breakout. 
Via Chartmill
A Look Into Incyte Inc's Price Over Earnings
Via Benzinga
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90. 
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Assessing Incyte: Insights From 11 Financial Analysts
Via Benzinga
Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
Incyte reports Q3 revenue of $1.04B, driven by strong Jakafi and Opzelura sales, and raises 2024 guidance amid competitive market challenges. 
Via Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
Exposures Product Safety
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Wall Street Lower Ahead Of Interest Rate Move
Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today. 
Via Talk Markets
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
Intel kept running late on yet another big deal. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.